How many _'s treatments know nutrition of tumour

How many _'s treatments know nutrition of tumour
According to scientist's latest result of study, researchers pass and improve a kind of commonly used chemical constitution against inflammation medicine, make it light in aspirin and therapeutic medicine of other arthritis to irritation of the stomach. This may be developed into a new kind of anticancer drug.
Ching-Shih Chen from Ohio state university tells reporter of Reuter, this kind of new medicine which is known as COX-2 inhibitor, can be used for formating new antineoplastic. They have already begun the development of this acute kind of medicine. COX-2 inhibitor including that cloth Lip river is fragrant and it is caught that naphthalene is generals are not all that the body of steroid resist inflammation medicine (AIDs) ,Traditional AIDs reduces inflammation through blocking the function of COX-2, but meanwhile this kind of medicine still blocks the function of COX-1 at the same time.
The main function of COX-1 is to protect the mucous membrane of stomach, so the function of COX-1 will produce the stomach irritation when being blocked. If COX-2 inhibitor can only inhibit the function of COX-2, can keep mucomembranous protective action of stomach of COX-1. Though COX-2 inhibitor is that a design is for relieving pain, since this kind of medicine steroid was sanctioned used in clinicking in the 1990s, multiple research have revealed already, this kind of medicine, both with preventing the function of tumour to other AIDs, especially to cancer of colon.
Chen,et al. first proposition can cause the cancer cell to wither to die through blocking the function of COX-2 enzyme. But in previous a research of steroid, Chen,et al. verifies, celecoxib and some other COX-2 inhibitors wither on the function of dying and have nothing to do with its the function on COX-2 to cells. In fact, though celecoxib and rofecoxib two kinds of medicines can both block the function of COX-2, only celecoxib function on tumour cells is stronger.
According to this new result of study, Chen proposes the function on tumour cells of COX-2 inhibitor is not to pass and block COX-2, but contribute through some other routes. The scientist of U.S.A. Ohio state thinks, the purpose of this research is to compare celecoxib with the chemical constitution of rofecoxib, it is analyzed that they impel the mechanism of the cancer cell death of prostate.
In delivering in the research report on " magazine of research institute of U.S.A.'s national cancer " published on December 4 this year, Chen,et al. has introduced the composition structure of celecoxib and rofecoxib in detail for the first time, then researchers develop new compound of the ath therapeutic prostate cancer on the basis of COX-2 inhibitor. Researchers verify the function on the cancer cell of COX-2 inhibitor has nothing to do with its the function on COX-2 enzyme.
Chen tells reporter of Reuter: "Our data reveal, celecoxib can inhibit other cell goals, and these are very important to existence of the cancer cell. Once these functions of cells will cause the cell death when losing. " In addition, researchers also find, spreading out compound that melt out does not influence cancer cell through blocking the function of COX-2 from these medicines. On the contrary, they are through influencing the signal in the cancer cell of prostate to conduct the thorough fare to contribute.
Raymond N from medical centre of Vanderbilt university. DuBois thinks, this research is a synthetic miracle of chemistry. But he warns again, also needs to carry on deeper research to this kind of compound at the same time. He says: "The reseach of such new medicine is very important in prevention of tumour. But also need further studying such new medicine, in order to guarantee its security and validity. "
|